{"name":"Janssen Vaccines & Prevention B.V.","slug":"janssen-vaccines-prevention-b-v","ticker":"","exchange":"","domain":"janssen.com","description":"Janssen Vaccines & Prevention B.V. is a leading biopharmaceutical company focused on the research, development, and production of innovative vaccines to prevent and treat infectious diseases. The company is part of the Janssen Pharmaceutical Companies of Johnson & Johnson, leveraging extensive expertise in vaccine science to address global health challenges.","hq":"Leiden","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"oncology","drugs":[{"name":"Ad26.ZEBOV 0.8*10^10 (vp)","genericName":"Ad26.ZEBOV 0.8*10^10 (vp)","slug":"ad26-zebov-0-8-10-10-vp","indication":"Ebola virus disease prevention (Zaire ebolavirus)","status":"phase_3"},{"name":"Ad26.ZIKV.001 1*10^11 vp","genericName":"Ad26.ZIKV.001 1*10^11 vp","slug":"ad26-zikv-001-1-10-11-vp","indication":"Other","status":"phase_1"},{"name":"Ad26.ZIKV.001 5*10^10 vp","genericName":"Ad26.ZIKV.001 5*10^10 vp","slug":"ad26-zikv-001-5-10-10-vp","indication":"Other","status":"phase_1"},{"name":"Ad26.Filo","genericName":"Ad26.Filo","slug":"ad26-filo","indication":"Ebola","status":"phase_1"},{"name":"Ad26.ZEBOV 2*10^10 (vp)","genericName":"Ad26.ZEBOV 2*10^10 (vp)","slug":"ad26-zebov-2-10-10-vp","indication":"Ebola virus disease prevention","status":"phase_3"},{"name":"Al(OH)3","genericName":"Al(OH)3","slug":"al-oh-3","indication":"Vaccine adjuvant in phase 3 vaccine development by Janssen Vaccines & Prevention B.V.","status":"phase_3"},{"name":"MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]","genericName":"MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]","slug":"mva-bn-filo-1-10-8-infectious-unit-inf-u","indication":"Prevention of Ebola virus disease","status":"phase_3"},{"name":"MVA-BN-Filo 5*10^7 Inf. U.","genericName":"MVA-BN-Filo 5*10^7 Inf. U.","slug":"mva-bn-filo-5-10-7-inf-u","indication":"Prevention of Ebola virus disease","status":"phase_3"},{"name":"Quadrivalent High-dose Influenza Vaccine","genericName":"Quadrivalent High-dose Influenza Vaccine","slug":"quadrivalent-high-dose-influenza-vaccine","indication":"Prevention of influenza disease in adults 65 years of age and older","status":"phase_3"},{"name":"RSV preF Protein 50 mcg","genericName":"RSV preF Protein 50 mcg","slug":"rsv-pref-protein-50-mcg","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Ad26.Mos.HIV","genericName":"Ad26.Mos.HIV","slug":"ad26-mos-hiv","indication":"HIV prevention","status":"phase_1"},{"name":"Ad26.RSV.preF-based vaccine","genericName":"Ad26.RSV.preF-based vaccine","slug":"ad26-rsv-pref-based-vaccine","indication":"Prevention of respiratory syncytial virus (RSV) infection in adults","status":"phase_3"}]}],"pipeline":[{"name":"Ad26.ZEBOV 0.8*10^10 (vp)","genericName":"Ad26.ZEBOV 0.8*10^10 (vp)","slug":"ad26-zebov-0-8-10-10-vp","phase":"phase_3","mechanism":"Ad26.ZEBOV is a replication-incompetent adenovirus serotype 26 vector expressing the Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus infection.","indications":["Ebola virus disease prevention (Zaire ebolavirus)"],"catalyst":""},{"name":"Ad26.ZIKV.001 1*10^11 vp","genericName":"Ad26.ZIKV.001 1*10^11 vp","slug":"ad26-zikv-001-1-10-11-vp","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Ad26.ZIKV.001 5*10^10 vp","genericName":"Ad26.ZIKV.001 5*10^10 vp","slug":"ad26-zikv-001-5-10-10-vp","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Ad26.Filo","genericName":"Ad26.Filo","slug":"ad26-filo","phase":"phase_1","mechanism":"Ad26.Filo is a viral vector vaccine that targets filoviruses.","indications":["Ebola"],"catalyst":""},{"name":"Ad26.Mos.HIV","genericName":"Ad26.Mos.HIV","slug":"ad26-mos-hiv","phase":"phase_1","mechanism":"HIV vaccine","indications":["HIV prevention"],"catalyst":""},{"name":"Ad26.RSV.preF-based vaccine","genericName":"Ad26.RSV.preF-based vaccine","slug":"ad26-rsv-pref-based-vaccine","phase":"phase_3","mechanism":"An adenovirus serotype 26 (Ad26)-based vaccine expressing the respiratory syncytial virus (RSV) prefusion F protein to elicit immune responses against RSV infection.","indications":["Prevention of respiratory syncytial virus (RSV) infection in adults","Prevention of RSV disease in older adults (≥60 years)"],"catalyst":""},{"name":"Ad26.ZEBOV 2*10^10 (vp)","genericName":"Ad26.ZEBOV 2*10^10 (vp)","slug":"ad26-zebov-2-10-10-vp","phase":"phase_3","mechanism":"Ad26.ZEBOV is a replication-incompetent adenovirus serotype 26 vector expressing the Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus.","indications":["Ebola virus disease prevention","Post-exposure prophylaxis for Ebola virus exposure"],"catalyst":""},{"name":"Al(OH)3","genericName":"Al(OH)3","slug":"al-oh-3","phase":"phase_3","mechanism":"Aluminum hydroxide acts as an adjuvant that enhances immune response by promoting antigen presentation and activating innate immunity.","indications":["Vaccine adjuvant in phase 3 vaccine development by Janssen Vaccines & Prevention B.V."],"catalyst":""},{"name":"MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]","genericName":"MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]","slug":"mva-bn-filo-1-10-8-infectious-unit-inf-u","phase":"phase_3","mechanism":"MVA-BN-Filo is a recombinant modified vaccinia Ankara (MVA) vaccine expressing Filovirus glycoproteins that primes the immune system to recognize and respond to Ebola and Marburg viruses.","indications":["Prevention of Ebola virus disease","Prevention of Marburg virus disease"],"catalyst":""},{"name":"MVA-BN-Filo 5*10^7 Inf. U.","genericName":"MVA-BN-Filo 5*10^7 Inf. U.","slug":"mva-bn-filo-5-10-7-inf-u","phase":"phase_3","mechanism":"MVA-BN-Filo is a recombinant modified vaccinia Ankara (MVA) vaccine expressing Filovirus glycoproteins that primes the immune system to recognize and respond to Ebola and Marburg viruses.","indications":["Prevention of Ebola virus disease","Prevention of Marburg virus disease"],"catalyst":""},{"name":"Quadrivalent High-dose Influenza Vaccine","genericName":"Quadrivalent High-dose Influenza Vaccine","slug":"quadrivalent-high-dose-influenza-vaccine","phase":"phase_3","mechanism":"This vaccine induces an immune response against multiple influenza strains.","indications":["Prevention of influenza disease in adults 65 years of age and older"],"catalyst":""},{"name":"RSV preF Protein 50 mcg","genericName":"RSV preF Protein 50 mcg","slug":"rsv-pref-protein-50-mcg","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPeXVIM19KS2p2S04wREY3R1pSUTJhRlNjaFVDOTg2OGpob2xjR2k1bXljVkxaMlBjX2x0LUJGb0RjVTFPOUJ0cXdnT3IwTmR2b016V3N5Z2tVbjVNY0lWc2dYbzNkMDAtYzdhRjJHQjRfMV9fb3R1bERyUzVCNHY1cnQzQk9jd0dMRHlxclFaNVI?oc=5","date":"2023-01-19","type":"trial","source":"IAVI","summary":"IAVI statement on results from Mosaico HIV vaccine trial - IAVI","headline":"IAVI statement on results from Mosaico HIV vaccine trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNZ0thYkM5Yk1OZUNSRjRmQzVmUjdYYUY3dU1fR0FBS0lzSDF2U29kSHhpVXRNRDBUaWJ0ci1iWU05Vzl1ek8zWU1mNjFaNjdjSGZSa2tmVUdfYWdGd05JZGxNYjcxVGRPVTVUMnpON2ZkVzB4Q281aDBkdnlobC1zcTRHTk4yMHVfM2E4MS1JRG1faGFJbWRQblZxOXJnX3pEbmJ0TmthOThoQm8?oc=5","date":"2023-01-18","type":"trial","source":"National Institutes of Health (.gov)","summary":"Experimental HIV vaccine regimen safe but ineffective, study finds - National Institutes of Health (.gov)","headline":"Experimental HIV vaccine regimen safe but ineffective, study finds - National Institutes of Health (.gov)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1idnJzZ2hVcGJSSy1QWmFPa1EzV0tKVEVXNHBfeDB0N2I5aTdySmI2OWZZVkVYNHd3eHczaDZsdWNDLTVGRDJUREljRlcwNGNsOGY1aTIyWVJLQ2kxYUpV?oc=5","date":"2021-10-07","type":"pipeline","source":"Nature","summary":"SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques - Nature","headline":"SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxOdGNHVnVQbmVkTFViNTBoeWx0cUN2QzVOcDFiRmpOTExCeVFQQlR4YWtaYVpwa09YVWU5T2FuMTdldnpoWlozZHhVSXc0dmlwTUVmWS1WeXNuVVM4VGZpNDNtc3RBUzJqNnRBd2JrbXhnVFNUQXQ4ZFlDX3RYNlZKa1FwYWxRSHMtMGhpdndHemFzWnhJRDNLRjhYYzVpdGhjcmc5b0xQZWxTZElZYlpTY2RGNHl4dV9wOU1rYmFsYTdqblpjTk5XcFZ3MTZpTWUyc1hMMEFYWjY2aTF2QjBrN2RYOEQtbFJmcGtRZXp2TGtQdHZpc1p4c0pRMHNIa0VwY0sxWW96VkZQMk1hbnc3cC1IZmpkTklYOTFkcG5vNVRzQQ?oc=5","date":"2021-08-31","type":"trial","source":"PR Newswire","summary":"Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa - PR Newswire","headline":"Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQWjUzMy1OUWZKNUZtSjludjBTWFJPWUYxZzl4M2ROQkdQZm5YT0RpX3p0TUJpMGtCMXgtNi1LUjNPa2xnQTU2LWRDV3J1dzRkakhwZkZmdnFfLWJfR0JSTTVnZHNFSzNBYjRNVGJ5NFpnSDRNTVQ1dmxJdkM2X1c2UEtCZFE?oc=5","date":"2021-08-11","type":"trial","source":"UKNow","summary":"UK Selected as Site for COVID-19 Vaccine Booster Study - UKNow","headline":"UK Selected as Site for COVID-19 Vaccine Booster Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE1VSWxMMDliZF81eE11blhFWmFHSGt6NTJKdThEYU1Oc3JuajROSG1CS2JFQmh1QUFBdWNuUHJoTUNodmtSWUhtR0c3b0V4VkJieUZPRmpJU2lMb1hqWk1UWHJJRkpBV0VQbWFDcA?oc=5","date":"2020-07-30","type":"pipeline","source":"Harvard Medical School","summary":"A Critical Step toward Protection - Harvard Medical School","headline":"A Critical Step toward Protection","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOby1IMkFMdTVkNm1PdTUzZ0ZKcWVPUV9EOG1ZdzVLamJnVWhjaVhJaUZQdmluUndSV1NoMDhWQVd1WmdjcXkyN29PM05hLXRlYU9OdUQ3RXNaS3d5bTZfenNmMFNoY0tnU2RSVUM2cVhZVGp2Z3NiUk50djd0NmtjYTdCOG1KZ3dUdWtYOGwtZDdRSF9JYllNOXhaWnBKZktqeHJ1UV96dVpLbDJMa1Q0U0E4aUF5NDRxTGRzVGF3aG82c3lYWjNETmJjMEcyWWNUbE9HRTZiaw?oc=5","date":"2020-07-01","type":"regulatory","source":"Johnson & Johnson","summary":"Johnson & Johnson Announces European Commission Approval for Janssen’s Preventive Ebola Vaccine - Johnson & Johnson","headline":"Johnson & Johnson Announces European Commission Approval for Janssen’s Preventive Ebola Vaccine - Johnson & Johnson","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOSng0SThkQTUyNTQ4aXBCYTZkbDk3SjBUQlFFOUxaOFBpM2l1bHQ2enlCNHZweHVhaC1kTmg3ZEFjRThHazlNRUlJbzJtc3p5bjhOQkVuM2hic1VSdFFMWFNuQW50a0x4czVuVUVjZUNybDBRWElBUnhuN2kzYW5wSnVYSUZ1MlN2UVhneWhlTmVHazhyaDNMZWlSbWozelBfWk02OWVGbTdDM0pKeHBzNEk0OF9Ic1pKQXhBbVVOOA?oc=5","date":"2020-03-31","type":"pipeline","source":"Science | AAAS","summary":"The $1 billion bet: Pharma giant and U.S. government team up in all-out coronavirus vaccine push - Science | AAAS","headline":"The $1 billion bet: Pharma giant and U.S. government team up in all-out coronavirus vaccine push - Science | AAAS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE43bkUzNmpfbGhWNjF6QVh0X1BoSHpDRUh1S2VtSzR3NjZyaFlyMzlFVkY3Mzk2QTZRd2QzUG9vMk1PVDB0ZWQySGVEajNXU0VMRmNnOEE0RjRHNWZEa0NOalhraTF0T0hGWlM3SFc3R0YxdnpoSUdBc1BiSG0?oc=5","date":"2019-10-14","type":"pipeline","source":"PharmaLive","summary":"Johnson & Johnson 2019: Operation Pharma Growth - PharmaLive","headline":"Johnson & Johnson 2019: Operation Pharma Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE04SnJXeGxVaVdjN0o0ektjaktCUWZfSzlnZFZPX1lNVVBuNDFXUHVhM0pRQnNpLTlmeE0yaXpCU2ZYZy1RNGVVbmZKUHJTdG10U05xSl9yS0hmMXY5VkdONEp2dTlBNlFWUkZpSQ?oc=5","date":"2019-01-20","type":"pipeline","source":"CEPI","summary":"Joining Forces with CEPI To Address Epidemic Threat - CEPI","headline":"Joining Forces with CEPI To Address Epidemic Threat","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2018-07-05","type":"pipeline","source":"Newswise","summary":"Preventative HIV Vaccine Candidate Triggers Desired Immune Responses in Humans and Monkeys, and Protects Monkeys from Infection | Newswise - Newswise","headline":"Preventative HIV Vaccine Candidate Triggers Desired Immune Responses in Humans and Monkeys, and Protects Monkeys from In","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE43UVYwNzBmbFdQWGloa1oxb2t2cV95eGRGZGNYWjI5VW1PSTNPLUJTVVIxNVhSXzFNLVZ2MkwxdnhyVDVYeHNFeFgtMENVQ1g5X1JENnMyaHZvbzE3TXpZTnpNa2hYQzhfQmJVOF9YTXYyR0p1akFv?oc=5","date":"2017-12-01","type":"trial","source":"Ragon Institute","summary":"Clinical Efficacy Trial of Ragon Institute-Supported HIV Vaccine Underway in Africa - Ragon Institute","headline":"Clinical Efficacy Trial of Ragon Institute-Supported HIV Vaccine Underway in Africa","sentiment":"neutral"}],"patents":[],"drugCount":12,"phaseCounts":{"phase_3":7,"phase_1":5},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}